Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.
Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5
Oracle Beats Q4 Expectations, But Heavy AI Spending Spooks Investors 📉 Stock Down 10% in Premarket
US Open: May Inflation Limits Declines
Food Better than Tech❓Cracker Barrel Surges 32% After Crushing Q3 Earnings 🍳 📈
Photronics after 50% crash📉 Deep value on semiconductors market or a value trap?